<p>When Joe DeMayo’s donated kidney started to fail earlier than expected, he didn’t know that the drug he was taking could’ve left him vulnerable — and that one of the most formidable drug regulators in the world may have failed to protect him.<br><a href="https://www.propublica.org/article/fda-tacrolimus-kidney-transplant-patient?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post" rel="nofollow" class="ellipsis" title="www.propublica.org/article/fda-tacrolimus-kidney-transplant-patient?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post"><span class="invisible">https://</span><span class="ellipsis">www.propublica.org/article/fda</span><span class="invisible">-tacrolimus-kidney-transplant-patient?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post</span></a></p><p><a href="/tags/news/" rel="tag">#News</a> <a href="/tags/health/" rel="tag">#Health</a> <a href="/tags/fda/" rel="tag">#FDA</a> <a href="/tags/kidneydonation/" rel="tag">#KidneyDonation</a> <a href="/tags/medicine/" rel="tag">#Medicine</a> <a href="/tags/drugs/" rel="tag">#Drugs</a> <a href="/tags/safety/" rel="tag">#Safety</a></p>